Inhibrx Biosciences, INC Form 4 insider transactions
NASDAQ
Director Kimberly Manhard received stock options for 30,000 shares of Inhibrx Biosciences common stock following the merger with a Sanofi subsidiary.
NASDAQ
Following the distribution of Inhibrx Biosciences shares and a merger with Sanofi, CEO Mark Lappe reports acquiring shares through trusts and receiving a stock option grant.
NASDAQ
Form 4: Inhibrx Biosciences Director Reports Acquisition of Shares and Stock Options Following Sanofi Merger
Director Jon Faiz Kayyem reports acquiring shares and stock options in Inhibrx Biosciences following the distribution of shares related to the merger with Sanofi.
NASDAQ
Form 4: Forsyth Acquires 149,564 Shares of Inhibrx Biosciences Following Distribution from Inhibrx, Inc.
Director Douglas Forsyth acquires 149,564 shares of Inhibrx Biosciences due to the distribution of shares from Inhibrx, Inc. and receives a stock option for 30,000 shares.
NASDAQ
Chief Scientific Officer Brendan P. Eckelman reports acquisition of Inhibrx Biosciences shares and stock options following the distribution of shares related to the Sanofi merger.
NASDAQ
Following the merger of Inhibrx, Inc. with a Sanofi subsidiary, CFO Kelly Deck received stock options for 175,000 shares.